Clinical Trials Sponsored by Institut Cancerologie de l'Ouest

Total 346 results

Institut Cancerologie de l'Ouest

Active, not recruiting

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology (EDHITO)

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Advanced Non-small Cell Lung Cancer | Immune Checkpoint Inhibitors | Therapeutic Patient Education | Immune-related Adverse Event

France
Institut Cancerologie de l'Ouest

Completed

Long-term Evaluation of the Quality of Life of Former Patients Treated With Orthopedic Surgery, With or Without Radiotherapy (STARTos)

Osteosarcoma in Children

France
Institut Cancerologie de l'Ouest

Terminated

Electrotherapy in the Management of Myofascial Syndrome (MODYMYO)

Breast Cancer

France
Institut Cancerologie de l'Ouest

Completed

Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncer (ELCCA-II)

Melanoma | Breast Cancer

France
Institut Cancerologie de l'Ouest

Completed

Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer (PAMELA70)

Toxicity | Pancreatic Metastatic Cancer

France
Institut Cancerologie de l'Ouest

Completed

Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer (GANEA2)

Breast Cancer

France
Institut Cancerologie de l'Ouest

Completed

Prospective Evaluation of the Impact on Patients' Quality of Life of a 12-Week Adapted Physical Activity Program (APA) (APA)

Sports Physical Therapy

France
Institut Cancerologie de l'Ouest

Completed

Intravenous Chemotherapy and Plant-based Dietary Supplements (CIVCAP)

Breast Cancer

France
Institut Cancerologie de l'Ouest

Completed

Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+ (TAM)

Non Metastatic Breast Cancer

France
Institut Cancerologie de l'Ouest

Completed

Satisfaction and QUality of Life After Breast REconstruction (SQUARE)

Breast Neoplasm Female | Mammaplasty

France
Institut Cancerologie de l'Ouest

Completed

Anesthesia Feasibility Study With the CONCERT-CL® Station (CONCERT)

Cancer | Surgery

France
Institut Cancerologie de l'Ouest

Completed

Retroprospective Real Life Observatory of Eribulin (ReProLine)

Metastatic Breast Cancer

France
Institut Cancerologie de l'Ouest

Terminated

Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy (BioConnect)

Cancer

France
Institut Cancerologie de l'Ouest

Completed

Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer (CAMARA)

Iron Deficiency Anemia

France
Institut Cancerologie de l'Ouest

Completed

Geriatric Determinants of General Repercussion of Radiotherapy for Patient Over 75 Years With Prostate Cancer (PROGERAD)

Prostate Cancer

France
Institut Cancerologie de l'Ouest

Completed

ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma (GEMO)

Prostate Adenocarcinoma

France
Institut Cancerologie de l'Ouest
ANSES

Recruiting

Socioeconomic Determinants of the Chemical Exposome and Its Genotoxic Effects in Children (PESTIFOL)

Healthy Volunteer Children

France
Institut Cancerologie de l'Ouest
AstraZeneca

Active, not recruiting

Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) (POSTCARD)

Bone Metastases | Prostate Cancer Patients | Node; Prostate

France
Institut Cancerologie de l'Ouest
Esteve

Recruiting

OP2C : Prialt® Observatory in Clinical Practice (OP2C)

Refractory Pain

France
Institut Cancerologie de l'Ouest
ATONCO

Completed

Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC) (PERTINENCE)

Bladder Cancer

France
Institut Cancerologie de l'Ouest
Diagnostica Stago

Recruiting

Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk (THROMBIN)

Solid Carcinoma

France
Institut Cancerologie de l'Ouest
Grünenthal GmbH

Not yet recruiting

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy (CAPNEUCHIM)

Chemotherapy-induced Peripheral Neuropathy
Institut Cancerologie de l'Ouest
PHRC-I

Recruiting

Management of the Lack of Blood Return on a Central Venous Catheter (CVC) Before Chemotherapy (CATAREV-B)

Catheter Dysfunction

France
Institut Cancerologie de l'Ouest
SIRIC ILIAD

Completed

[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers (EITHICS)

Triple Negative Breast Cancer

France
Institut Cancerologie de l'Ouest
Fondation ARC

Active, not recruiting

64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)

Rectal Cancer

France
Institut Cancerologie de l'Ouest
Grünenthal GmbH

Completed

Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery (CAPTRANE)

Breast Cancer Patient

France
Institut Cancerologie de l'Ouest
National Cancer Institute, France

Active, not recruiting

Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery (RESPIRE)

Melanoma | Breast Cancer | Gynecologic Cancer | Digestive Cancer

France
Institut Cancerologie de l'Ouest

Completed

Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

France
Institut Cancerologie de l'Ouest

Unknown

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

Colorectal Cancer | Neurotoxicity | Chemotherapeutic Agent Toxicity

France
Institut Cancerologie de l'Ouest
Astellas Pharma Inc

Active, not recruiting

Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS)

Prostate Cancer

France
University Hospital, Tours
Institut Cancerologie de l'Ouest

Terminated

A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer (DHALYA)

Metastatic Breast Cancer | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor | HER-2 Negative Tumor

France
Institut Cancerologie de l'Ouest
University of Poitiers

Unknown

Cancer Related Cognitive Impairment (APACO)

Patients Treated for Cancer

France
Institut Cancerologie de l'Ouest
Hospices Civils de Lyon

Completed

Time to Surgery and Survival Outcomes for Patients With Resected Colorectal Carcinoma: Multicenter Study (BIG RENAPE) (DELARC)

Colo-rectal Cancer

France
Celtic Biotech Ltd
Institut de Cancérologie de l'Ouest

Not yet recruiting

Open Label Clinical Trial of Intravenous Crotoxin Part 3

Cancer

France
Institut Cancerologie de l'Ouest
Telix Pharmaceutical; SIRIC ILIAD

Recruiting

Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients (OPALESCENCE)

Triple Negative Breast Cancer

France
Institut Cancerologie de l'Ouest
Merck Sharp & Dohme LLC

Terminated

Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma (UFT RT Phase 3)

Rectal Cancer | Stage II/III | T3 or T4 (Only Anal Extension) Rectal Cancer | N0-2 | M0

France
Institut Cancerologie de l'Ouest
Direction Générale de l'Offre de Soins

Unknown

Prophylactic Noninvasive Ventilation in vs Postoperative Standard Care in High Risk Patients According to ARISCAT Score (ANTICIPUSC)

Pulmonary Complication | Surgical Patients

France
Institut Cancerologie de l'Ouest
Direction Générale de l'Offre de Soins

Recruiting

Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma (GANEA3)

Invasive Breast Cancer | Axillary Metastases

France
Institut Cancerologie de l'Ouest
Direction Générale de l'Offre de Soins

Terminated

Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse (FIGARO)

Invasive Breast Cancer | Sentinel Lymph Node Biopsy | Ipsilateral Recurrence

France
Nantes University Hospital
Gilead Sciences; Institut Cancerologie de l'Ouest

Withdrawn

Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia (EPRALLO)

Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Institut Cancerologie de l'Ouest
Hospices Civils de Lyon; Centre Antoine Lacassagne

Terminated

Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma (FOLAGLI)

Glioblastoma | Grade IV Astrocytoma

France
Institut Cancerologie de l'Ouest
Fondation ARC; University of Angers, GRANEM

Unknown

Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs (TOPTACOS)

Stage III Renal Cell Cancer | Metastatic Renal Cancer

France
Institut Cancerologie de l'Ouest
Astellas Pharma Inc; Direction Générale de l'Offre de Soins

Active, not recruiting

Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients (OLIGOPELVIS2)

Prostate Cancer | Oligometastasis

France
Institut de Cancérologie de Lorraine

Recruiting

Comparative Study of the Quality of Life of Patients Suffering From OTOTOXICITY Due to Chemotherapy Based on Platinum Salts Fitted With a Hearing Aid Compared to Those Not Fitted. (PROTOTOX)

Quality of Life | Cancer | Hearing Disorders | Ototoxicity, Drug-Induced

France
Institut de Cancérologie de Lorraine

Not yet recruiting

Personalized Preventive Support for Cognitive Impairment in Non-Metastatic Breast Cancer (EFACog) (EFACog)

No Metastatic Breast Cancer

France
Institut de Cancérologie de Lorraine

Recruiting

Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia (PhotodiVIN)

Vulvar Intraepithelial Neoplasia | Vulvar High Grade Squamous Intraepithelial Lesion | Differentiated Vulvar Intraepithelial Neoplasia

France
Institut de Cancérologie de Lorraine

Recruiting

Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL) (PERCIMEL)

Melanoma

France
Institut de Cancérologie de Lorraine

Recruiting

Bonds Between Circulating Tumoral ADN (ctDNA) and the Development of Peritoneal Carcinomatosis for Patients Under PIPAC (PIPADN)

Peritoneal Carcinomatosis

France
Institut de Cancérologie de Lorraine

Completed

Unusual Toxicity Induced by Radiotherapy (CRYOTOX)

Cancer

France
Institut de Cancérologie de Lorraine

Completed

Analgesia Nociception Index (ANI) After Unilateral Radical Mastectomy as an Evaluation of Paravertebral Block Failure (ANIBPV)

Breast Cancer

France

Clinical Trials Sponsored by Institut Cancerologie de l'Ouest

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations